Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0268318 (
ICP
)
10,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A speciation method was developed for selenious acid,
selenic acid
, trimethylselenonium ion (TMSe) and selenomethionine (SeMet). Separation of the four selenium species was achieved by HPLC on an ESA Anion III anion-exchange column using aqueous mobile phase of 5.5 mmol/L ammonium citrate at pH 5.5 with a flow rate of 1.5 mL/min. Under the optimal conditions, the four selenium species were separated within 8 minutes. On-line selenium-specific detection was carried out with an inductively coupled plasma mass spectrometer (ICP-MS) or a flame atomic absorption spectrometer (FAAS). The detection limits of HPLC-FAAS were approximately rho(Se) = 1 mg/L for each compound (100 microL injection). To increase the nebulization efficiency of the
ICP
-MS, the Meinhard concentric nebulizer was replaced by an ultrasonic nebulizer (USN). The
ICP
-MS signal intensity was increased by a factor of 7 for selenious acid and 24 to 31 for TMSe, SeMet and
selenic acid
with the USN compared to that with the Meinhard nebulizer. The detection limits of the HPLC-USN-
ICP
-MS were rho(Se) = 0.08 microgram/L for TMSe, rho(Se) = 0.34 microgram/L for selenious acid, rho(Se) = 0.18 microgram/L for SeMet and rho(Se) = 0.07 microgram/L for
selenic acid
.
...
PMID:Determination of selenium compounds by HPLC with ICP-MS or FAAS as selenium-specific detector. 1254 16